Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00363311 · ClinicalTrials.gov registry record · Phase 4
Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In Men
A Phase 4 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 4
- Development phase
- 302
- Enrollment target
NCT00363311 is a Phase 4 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 302 participants.
The verdict
NCT00363311, a Phase 4 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 302 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the effect of dutasteride on the inhibition of low-risk, localized prostate cancer progression in men who would otherwise receive no active therapy (expectant management).
Interventions
- DRUG Matching placebo
- DRUG Dutasteride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 302 participants |
| Start Date | 2006-07 |
| Est. Completion | 2010-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00363311
The ClinicalTrials.gov registry entry for NCT00363311 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 302 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Matching placebo is the first listed.
NCT00363311 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00363311 about?
NCT00363311 is a clinical study titled "Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In Men". The purpose of this study is to examine the effect of dutasteride on the inhibition of low-risk, localized prostate cancer progression in men who would otherwise receive no active therapy (expectant management).
What is the current status of trial NCT00363311?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 302 participants. The study started on 2006-07. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00363311?
The interventions under investigation include: Matching placebo (DRUG), Dutasteride (DRUG).
Who is sponsoring clinical trial NCT00363311?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.